Sort
4,870 grants matching “glp 1”
Developing A Novel Therapy for Diabetic Retinopathy
$785,308Danyang Chen · Charlesson, Llp · R44 · FY2015 · EY
Pediatric toxicity and efficacy in long-term systemic treatment with anti-sense
$785,176John N Van Den Anker · Children'S Research Institute · U54 · FY2014 · HD
Epigenetic Reprogramming in HIV-Associated Cardio-Vascular Disease
$784,578Michael Ilya Bukrinsky · George Washington University · R01 · FY2020 · HL
Clinical Development of Elafin as a PAH Therapy
$784,522Roham Zamanian · Stanford University · P01 · FY2017 · HL
Beyond BMI: Role of Body Composition, Coronary Microvascular Dysfunction and HFpEF in Characterizing Cardiometabolic Disease Phenotypes
$784,362Viviany R Taqueti · Brigham And Women'S Hospital · R01 · FY2025 · HL
Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer'sDisease
$784,203Pazhani Sundaram · Recombinant Technologies, Llc · R44 · FY2024 · AG
PERCUTANEOUS TREATMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE WITH IMPLANTATION OF MULTIPLE, BALLOON-EXPANDABLE, DRUG-ELUTING BIORESORBABLE SCAFFOLDS (the Efemoral Vascular Scaffold System)
$783,064Lewis Schwartz · Efemoral Medical, Inc. · R44 · FY2022 · HL
Regulation of Body Composition and Energy Metabolism by LH With Aging
$782,467Daria Lizneva · Icahn School Of Medicine At Mount Sinai · U19 · FY2024 · AG
Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur
$781,772Garry John Southan · Radikal Therapeutics, Inc. · U01 · FY2017 · ES
Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry
$781,732Jose M Mejia Oneto · Shasqi, Inc. · R44 · FY2023 · CA
Design And Development Of Experimental Therapeutics
$781,688Nigel H. Greig · Aging · Z01 · FY2007 · AG
Neuroprotective And Neurorestorative Signaling Mechanisms
$781,688Mark P Mattson · Aging · Z01 · FY2007 · AG
Coronary Post-Dilatation Catheter
$781,382William Combs · 3dt Holdings, Llc · R44 · FY2016 · HL
Impact of a Glucagon-Like Peptide-1 Receptor Agonist administration on SIV/HIV pathogenesis and ART
$780,853Ivona Pandrea · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · DK
Core C - The University of Texas Medical Branch at Galveston
$780,615Thomas William Geisbert · Henry M. Jackson Fdn For The Adv Mil/Med · U19 · FY2019 · AI
Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapy
$779,869Samarendra Kumar Mohanty · Nanoscope Technologies, Llc · R44 · FY2020 · EY
Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer.
$778,770Bruce Dale Weintraub · Trophogen, Inc. · R44 · FY2019 · CA
Cost-Effectiveness of Food is Medicine Interventions to Improve Diet and Reduce Cardiometabolic Diseases
$778,531Dariush Mozaffarian · Tufts University Boston · R01 · FY2024 · HL
Optimizing the Safety of the Newer Diabetes Medications in Patients with Diabetes and Kidney Disease
$778,487Julie Paik · Brigham And Women'S Hospital · R01 · FY2024 · DK
Development and Pre-Clinical Trial Qualification of a Pediatric Pump-Lung System for Children
$778,362Bartley Perry Griffith · University Of Maryland Baltimore · R01 · FY2019 · HL
Epigenetic Reprogramming in HIV-Associated Cardio-Vascular Disease
$777,389Michael Ilya Bukrinsky · George Washington University · R01 · FY2021 · HL
AAV-mediated gene therapy for GM2-gangliodoses
$776,812Miguel S Esteves · Univ Of Massachusetts Med Sch Worcester · U01 · FY2012 · NS
Development of AAV-AIBP for neuroprotection in glaucoma
$776,782Wonkyu Ju · University Of California, San Diego · UG3 · FY2023 · NS
Optimized lactoferrin for treatment of intracerebral hemorrhage
$776,623Marian L Kruzel · Pharmareview Corporation · R42 · FY2016 · NS
Regulation of Adipose Tissue Plasticity by Pericyte GIPR
$776,568Jonathan E Campbell · Duke University · R01 · FY2025 · DK